Neuroleptic malignant syndrome associated with metoclopramide in a burn patient

Journal of Burn Care and Research

Volumn 27, Issue 2, 2006, Pages 237-241

  Nachreiner, Ryan ^a   Balledux, Jeroen ^a   Zieger, Madeline ^a   Viegas, Oscar ^a   Sood, Rajiv ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; METOCLOPRAMIDE; NEUROLEPTIC AGENT; ANTIEMETIC AGENT; CENTRAL MUSCLE RELAXANT;

ADULT; ARTICLE; BODY TEMPERATURE; BURN; BURN PATIENT; CASE REPORT; DEBRIDEMENT; DOPAMINE RELEASE; HEMODYNAMICS; HUMAN; MALE; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; SIDE EFFECT; VOMITING;

ADULT; ANTIEMETICS; BURNS; DANTROLENE; HUMANS; MALE; METOCLOPRAMIDE; MUSCLE RELAXANTS, CENTRAL; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 33745372257     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/01.BCR.0000202644.17987.3F     Document Type: Article

References (13)

1. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-35.
2. Still J, Friedman B, Law E, Deppe S, Epperly N, Orlet H. Neuroleptic malignant syndrome in a burn patient. Burns 1998;24:573-5.
3. Delay J, Deniker P. Drug-induced extrapyramidal syndromes. In Vinken P, Bruyn G, eds. Handbook of clinical neurology: disease of the basal ganglia. North Holland: Elsevier, 1968. p. 248-66.
4. Friedman L, Weinrauch L, D'Elia J. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med 1987;147:1495-7.
5. Henderson A, Longdon P. Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene. Aust NZ J Med 1991;21:742-3.
6. Lee T, Tang L. Neuroleptic malignant syndrome. J Neurol 1988;235:324-5.
7. Ebadi M, Pfeiffer R, Murrin L. Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmac 1990;21:367-83.
8. Gurrera R. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002;25:183-93.
9. Chan C. Dantrolene sodium and hepatic injury. Neurology 1990;1427-32.
10. Caroff S, Rosenberg H, Fletcher J, Heiman-Peterson T, Mann S. malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987;67:20-5.
11. Araki M, Tagaki A, Higuchi I, Sugita H. Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology. Neurology 1988;38:297-301.
12. Litman R, Rosenberg H. Malignant hyperthermia; update on susceptibility testing. JAMA 2005;293:2918-24.
13. Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psych 1991;158:850-3.